Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia

Additional data from recently reported positive Phase 3 RESILIENT trial will be presentedCHATHAM, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer, will present at The 6th International Congress on Controversies in Fibromyalgia in Brussels, Belgium on March 7, 2024. The pres

Related Keywords

Belgium ,Brussels ,Bruxelles Capitale ,Ben Shannon ,Seth Lederman ,Jessica Morris ,Peter Vozzo ,Zembrace Symtouch ,Tonix Pharmaceuticals ,Exchange Commission ,Nasdaq ,Drug Administration ,Tonix Pharmaceuticals Holding Corp ,International Congress On Controversies In Fibromyalgia ,Pharmaceuticals Holding ,Chief Executive Officer ,International Congress ,Scientific Presentations ,New Drug Application ,Breakthrough Therapy ,Private Securities Litigation Reform Act ,Annual Report ,